Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Dawson's Creek' Star Has Cancer; Radiotherapy Tattoos; Case of 'Petticoat' Cancer

2.

Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.

3.

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

4.

Breast Density Laws Fall Short Raising Additional Screening

5.

Exercise could ease symptoms for people with chronic lymphocytic leukemia, support and guidance are lacking: Study


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot